Well, this explains the sudden move, hope it holds, I own some
12:01 ET Guilford Pharm receives European marketing authorization for Gliadel (GLFD) 5.38 +0.06: Co announced that its proprietary treatment for brain cancer, Gliadel Wafer, has been granted extended marketing authorization in Europe to include use in newly- diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Under the mutual recognition procedure, Gliadel has been approved for use in the following countries: France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain and the United Kingdom. Gliadel was previously authorized for use only in recurrent surgery for glioblastoma multiforme |
